Bristol Myers Squibb (BMY) closed the latest trading day at $56.30, indicating a -0.95% change from the previous session's end. The stock fell short of the S&P 500, which registered a loss of 0.09% for the day. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, lost 0.1%.Heading into today, shares of the biopharmaceutical company had lost 1.8% over the past month, outpacing the Medical sector's loss of 2.1% and lagging the S&P 500's loss of 0.29% in that time.Investors will be eagerly watc ...

If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there are many other stocks out there that pay much higher than that -- and they aren't risky investments to hold in your portfolio.For retirees, three blue chip stocks that can be ideal options for your portfolio include Bristol Myers Squibb (BMY -0.56%), Enbridge (ENB 0.40%), and Coca-Cola (KO -0.35%). These divid ...

One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power. A person who starts out even with a relatively modest sum, like $250, then progressively (and consistently) invests more over time, and stays invested for the long term, will typically see their efforts yield significant returns -- provided they choose the right companies to buy.But which ones are the "right" ones to invest in? Let's consider two compan ...

It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug development is a frequently laborious and expensive process that can swallow vast amounts of capital.Yet there is a clutch of companies at the top of the industry not only paying distributions regularly, but also lately increasing them on a consistent basis.Two of these, Bristol Myers Squibb (BMY -1.41%) and Eli Lilly (LLY -1.79%), just declared dividend raises. What's more, since the new ...

Agreement Details - BioArctic has entered into a global exclusive license agreement with Bristol Myers Squibb for its PyroGlu-Aβ antibody program, including BAN1503 and BAN2803 [1] - The agreement includes a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments, with tiered low double-digit royalties on global product sales [1][2] - Bristol Myers Squibb will be solely responsible for the development and commercialization of BAN1503 and BAN2803 worldwide, while BioArctic retains an option to co-commercialize in the Nordic region [2] Technology and Program Overview - The PyroGlu-Aβ antibody program targets a specific truncated, pyroglutamate-modified form of amyloid-beta, which is highly prone to aggregation and contributes to Alzheimer's disease symptoms [3] - BAN2803 incorporates BioArctic's BrainTransporter technology, which utilizes the transferrin receptor (TfR) to optimize brain delivery of biotherapeutics across the blood-brain barrier [4] - The BrainTransporter technology has potential applications in various therapy areas for delivering biologic molecules, offering future partnering opportunities for BioArctic [5][8] Strategic Implications - The agreement with Bristol Myers Squibb marks the first license agreement involving BioArctic's BrainTransporter technology, specifically for PyroGlu-Aβ antibody treatments [5] - BioArctic retains all other rights to the BrainTransporter platform, which is being applied to several in-house drug projects and could be part of future collaborations [5][8] - The partnership aligns with Bristol Myers Squibb's strategy to strengthen and diversify its neuroscience portfolio, leveraging innovative approaches like the BrainTransporter technology [5] Company Background - BioArctic is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS [9] - The company co-developed Leqembi (lecanemab), the first drug proven to slow Alzheimer's progression, in partnership with Eisai [9] - BioArctic's research portfolio includes multiple projects utilizing its proprietary BrainTransporter technology to enhance treatment efficacy by actively transporting antibodies across the blood-brain barrier [9]

SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS") China on December 16th. The partnership was officially formalized with the signing of a collaboration agreement by Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, and Mr. Wen Yizhong, the head of the Innovative Medicines Division at BMS China and General Manager for BMS Hong Kong.This strategic al ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of BMY, PFE, A ...

PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by various factors, including the aging of the population, dietary choices, lifestyle changes, and the prevalence of Helicobacter pylori infection. Growth in the market is driven by an increase in demand for diagnostic tools, therapies, and supporting care in tandem with a rise in the number of diagnosed cases. A recen ...

Bristol-Myers Squibb Company (NYSE:BMY) Citi’s 2024 Global Healthcare Conference December 3, 2024 8:00 AM ET Company Participants Christopher Boerner - CEO and Board Chair David Elkins - EVP and CFO Conference Call Participants Geoff Meacham - Citi Mary Kate Davis - Citi Geoff Meacham Welcome to the first session of the First Annual Global Healthcare Conference at Citi. We're thrilled to be here and we're thrilled to have with us. My name is Geoff Meacham. I'm the Senior Biopharma Analyst and we have Mary ...

Bristol-Myers Squibb (BMY -0.08%) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With a large repertoire of medicines on the market, and a constant stream of programs approaching maturity and a shot at getting approved for sale, there's no question that the business will continue to create drugs that are in demand around the world.But solid companies don't always make for the perfect investments, especially when investors have outsized expectat ...